LSI is Officially Heading to Singapore — Register for LSI Asia '25 Today

Afferent Pharmaceuticals

First-in-class, small molecule compounds that successfully manage and treat chronic pain, by inhibiting P2X3 receptors.

Get a Demo and See the Full Profile

Get a demo today to see profiles of Afferent Pharmaceuticals plus 6116 other startups.

Learn More About Afferent Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups

More